Provided by Tiger Trade Technology Pte. Ltd.

Sutro Biopharma Inc

13.98
-1.5400-9.92%
Pre-market: 14.610.6300+4.51%07:11 EST
Volume:63.04K
Turnover:909.40K
Market Cap:119.10M
PE:-0.54
High:15.47
Open:15.27
Low:13.88
Close:15.52
52wk High:19.45
52wk Low:5.23
Shares:8.52M
Float Shares:6.10M
Volume Ratio:0.68
T/O Rate:1.03%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-25.8759
EPS(LYR):-29.6061
ROE:-1810.01%
ROA:-25.80%
PB:-1.36
PE(LYR):-0.47

Loading ...

Sutro Biopharma Announces Pricing of $110.0 Million Underwritten Offering

THOMSON REUTERS
·
1 hour ago

Sutro Biopharma Inc - Prices 7,868,383 Shares at $13.98 per Share

THOMSON REUTERS
·
1 hour ago

Press Release: Sutro Biopharma Announces Pricing of $110.0 million Underwritten Offering

Dow Jones
·
1 hour ago

Sutro Biopharma Raised to Market Outperform From Market Perform by Citizens

Dow Jones
·
Jan 20

Sutro Biopharma upgraded to Outperform from Market Perform at Citizens

TIPRANKS
·
Jan 20

Analysts Have Conflicting Sentiments on These Healthcare Companies: Sutro Biopharma (STRO) and Molina Healthcare (MOH)

TIPRANKS
·
Jan 16

Sutro Biopharma Is Maintained at Neutral by HC Wainwright & Co.

Dow Jones
·
Dec 22, 2025

Sutro Biopharma Inc : H.c. Wainwright Raises Target Price to $10 From $2

THOMSON REUTERS
·
Dec 22, 2025

Sutro Biopharma Completes 1-for-10 Reverse Stock Split

Reuters
·
Dec 18, 2025

Sutro Biopharma Regains Compliance With Nasdaq Minimum Bid Price Requirement

THOMSON REUTERS
·
Dec 18, 2025

Sutro Biopharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
Dec 17, 2025

Sutro Biopharma Enacts 1-for-10 Reverse Stock Split

Reuters
·
Dec 04, 2025

BRIEF-Sutro Biopharma Announces First Cohort Of Patients Dosed In Phase 1 Trial Of Stro-004

Reuters
·
Dec 03, 2025

Sutro Biopharma Doses First Patients in Phase 1 Trial of STRO-004 for TF-Expressing Solid Tumors

Reuters
·
Dec 03, 2025

Sutro Biopharma Inc - Initial Clinical Data Expected Mid-2026

THOMSON REUTERS
·
Dec 03, 2025

Sutro Biopharma Announces First Cohort of Patients Dosed in Phase 1 Trial of Stro-004, a Next-Generation Tissue Factor ADC, in Tf-Expressing Solid Tumors

THOMSON REUTERS
·
Dec 03, 2025

NASDAQ TRADE HALT HALT NEWS PENDING AT 07:50 PM

Reuters
·
Dec 03, 2025

BRIEF-Sutro Biopharma Announces 1-For-10 Reverse Stock Split

Reuters
·
Dec 01, 2025

Sutro Biopharma Q3 Revenue USD 9.693 Million

Reuters
·
Nov 20, 2025

Sutro Biopharma Unveils STRO-227 as First Dual-Payload ADC Targeting PTK7

Reuters
·
Nov 12, 2025